 Spyridon Mastroyannis
Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 9 | 2025 | 599 | 0.950 |
Why?
| | Sentinel Lymph Node | 3 | 2025 | 49 | 0.620 |
Why?
| | Endometrial Neoplasms | 3 | 2025 | 205 | 0.540 |
Why?
| | Sentinel Lymph Node Biopsy | 4 | 2025 | 117 | 0.450 |
Why?
| | Uterine Neoplasms | 3 | 2021 | 98 | 0.440 |
Why?
| | Genital Neoplasms, Female | 2 | 2024 | 100 | 0.350 |
Why?
| | Sarcoma, Endometrial Stromal | 2 | 2021 | 7 | 0.330 |
Why?
| | Hydatidiform Mole | 2 | 2020 | 3 | 0.310 |
Why?
| | Gestational Trophoblastic Disease | 2 | 2020 | 6 | 0.310 |
Why?
| | Lymph Node Excision | 3 | 2021 | 173 | 0.310 |
Why?
| | Granulosa Cell Tumor | 2 | 2020 | 6 | 0.310 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 1166 | 0.240 |
Why?
| | Hysterectomy | 3 | 2021 | 138 | 0.230 |
Why?
| | Carcinoma, Endometrioid | 1 | 2025 | 49 | 0.210 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 156 | 0.200 |
Why?
| | Myeloid Cells | 1 | 2025 | 150 | 0.200 |
Why?
| | Enoxaparin | 1 | 2024 | 68 | 0.200 |
Why?
| | Prognosis | 7 | 2025 | 4383 | 0.180 |
Why?
| | Pyridones | 1 | 2024 | 210 | 0.180 |
Why?
| | Leiomyosarcoma | 1 | 2021 | 30 | 0.170 |
Why?
| | Vulvar Neoplasms | 1 | 2020 | 13 | 0.160 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2020 | 8 | 0.160 |
Why?
| | Vacuum Curettage | 1 | 2020 | 4 | 0.160 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 19 | 0.160 |
Why?
| | Pyrazoles | 1 | 2024 | 518 | 0.150 |
Why?
| | Organ Sparing Treatments | 1 | 2020 | 37 | 0.150 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 5 | 0.150 |
Why?
| | CA-125 Antigen | 1 | 2019 | 13 | 0.150 |
Why?
| | Neoplasm Staging | 5 | 2022 | 1492 | 0.140 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 76 | 0.140 |
Why?
| | Vaccines | 1 | 2023 | 389 | 0.140 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2018 | 14 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 103 | 0.140 |
Why?
| | Female | 24 | 2025 | 80076 | 0.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2018 | 52 | 0.130 |
Why?
| | Leuprolide | 1 | 2017 | 21 | 0.130 |
Why?
| | Lymphatic Metastasis | 3 | 2025 | 338 | 0.130 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2017 | 39 | 0.130 |
Why?
| | Middle Aged | 14 | 2025 | 36821 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 648 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2018 | 514 | 0.110 |
Why?
| | Retrospective Studies | 9 | 2025 | 17560 | 0.110 |
Why?
| | Estrogens | 1 | 2017 | 368 | 0.110 |
Why?
| | Succinate Dehydrogenase | 1 | 2015 | 65 | 0.110 |
Why?
| | Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2014 | 2 | 0.110 |
Why?
| | Pheochromocytoma | 1 | 2015 | 67 | 0.100 |
Why?
| | Cushing Syndrome | 1 | 2014 | 10 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5476 | 0.100 |
Why?
| | Age Determination by Skeleton | 1 | 2014 | 16 | 0.100 |
Why?
| | Paraganglioma | 1 | 2015 | 65 | 0.100 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2015 | 99 | 0.100 |
Why?
| | Bone Development | 1 | 2014 | 52 | 0.100 |
Why?
| | Humans | 25 | 2025 | 147293 | 0.100 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2014 | 125 | 0.100 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2014 | 147 | 0.100 |
Why?
| | Pituitary Neoplasms | 1 | 2015 | 190 | 0.090 |
Why?
| | Glucose Intolerance | 1 | 2014 | 142 | 0.090 |
Why?
| | Adenoma | 1 | 2015 | 219 | 0.090 |
Why?
| | Aged | 9 | 2025 | 26514 | 0.090 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 143 | 0.090 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2012 | 12 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 56 | 0.090 |
Why?
| | Fatty Liver | 1 | 2014 | 257 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2024 | 3022 | 0.080 |
Why?
| | Obesity | 2 | 2014 | 3149 | 0.080 |
Why?
| | Chorionic Gonadotropin | 2 | 2020 | 78 | 0.080 |
Why?
| | Adipose Tissue | 1 | 2014 | 646 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8430 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 615 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2022 | 429 | 0.070 |
Why?
| | SEER Program | 2 | 2020 | 232 | 0.070 |
Why?
| | Adult | 9 | 2025 | 41405 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2020 | 313 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1344 | 0.070 |
Why?
| | Bone Density | 1 | 2012 | 493 | 0.070 |
Why?
| | Registries | 3 | 2022 | 2434 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2019 | 2420 | 0.060 |
Why?
| | Survival Rate | 2 | 2021 | 2110 | 0.060 |
Why?
| | United States | 5 | 2022 | 16313 | 0.060 |
Why?
| | Liver | 1 | 2014 | 1916 | 0.060 |
Why?
| | BRCA1 Protein | 1 | 2025 | 83 | 0.050 |
Why?
| | Young Adult | 5 | 2020 | 14437 | 0.050 |
Why?
| | Brachytherapy | 1 | 2025 | 133 | 0.050 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2024 | 67 | 0.050 |
Why?
| | Adolescent | 6 | 2020 | 22825 | 0.050 |
Why?
| | Adoptive Transfer | 1 | 2023 | 200 | 0.050 |
Why?
| | Incidence | 2 | 2020 | 2954 | 0.050 |
Why?
| | Factor Xa Inhibitors | 1 | 2024 | 194 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2025 | 510 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 748 | 0.040 |
Why?
| | Dysgerminoma | 1 | 2020 | 6 | 0.040 |
Why?
| | Endodermal Sinus Tumor | 1 | 2020 | 10 | 0.040 |
Why?
| | Venous Thromboembolism | 1 | 2024 | 330 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 69 | 0.040 |
Why?
| | Fertility Preservation | 1 | 2020 | 57 | 0.040 |
Why?
| | Child | 5 | 2020 | 22979 | 0.040 |
Why?
| | Child, Preschool | 3 | 2020 | 12016 | 0.030 |
Why?
| | Cohort Studies | 2 | 2020 | 6099 | 0.030 |
Why?
| | Anticoagulants | 1 | 2024 | 751 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 975 | 0.030 |
Why?
| | Receptors, LH | 1 | 2017 | 9 | 0.030 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2017 | 17 | 0.030 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2017 | 52 | 0.030 |
Why?
| | Mice | 3 | 2025 | 18491 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2017 | 153 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2015 | 3153 | 0.030 |
Why?
| | Pregnancy | 2 | 2020 | 7274 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1386 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 11017 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 2017 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 780 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1443 | 0.030 |
Why?
| | Base Sequence | 1 | 2017 | 2175 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1504 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2015 | 180 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 414 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1730 | 0.020 |
Why?
| | Diet, High-Fat | 1 | 2014 | 267 | 0.020 |
Why?
| | Animals | 3 | 2025 | 38410 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2496 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 266 | 0.020 |
Why?
| | Male | 5 | 2020 | 73950 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3784 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2791 | 0.020 |
Why?
| | Infant | 1 | 2020 | 10194 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 6041 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 7173 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 11947 | 0.010 |
Why?
|
|
Mastroyannis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|